linjc16/ctgov huggingface dataset:
A Study of Nystatin in HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI) administered in an alternating regimen in this patient population.

Detailed Description
-----------------
Patients who have completed protocol FDA 103B are offered the option of receiving extended maintenance. Patients who have received no prior ddI are treated either with intravenous nystatin alone (at the same dose level administered in FDA 103B) or with a regimen of intravenous nystatin and ddI alternating on 3-week cycles. Treatment continues for 12 weeks.

Official Title
-----------------
Extended Maintenance Protocol for Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection (NOTE: Continuation Study Intended Only for Patients Who Have Completed FDA 103B)

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Nystatin
* Drug: Didanosine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: Completed 12 weeks of therapy with intravenous nystatin on protocol FDA 103B. No evidence of toxicity or progression of disease on protocol FDA 103B. (See protocol FDA 103B for initial entry requirements.) Active drug or alcohol abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nystatin|nan|
|Drug: Didanosine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nystatin, Didanosine, Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, AIDS-Related Complex
Galantamine Executive Function in Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to determine whether galantamine stabilizes or improves thinking abilities in individuals with Parkinson's disease. Individuals included in the study have minor complaints about thinking such as problems with concentration or memory but do not have dementia. This medication has been shown to have a positive effect on stabilizing memory in individuals with Alzheimer's disease. It is FDA approved for use in elderly individuals with Alzheimer's disease. It is hypothesized that galantamine will stabilize or improve executive and attentional functions in individuals with Parkinson's.

Detailed Description
-----------------
While several cholinesterase inhibitors have effectiveness in Alzheimer's disease (AD), galantamine is unique since it has a dual mode of action: inhibition of acetylcholinesterase and modulation of nicotinic acetylcholine receptors.As Parkinson's disease (PD) impacts frontal systems, executive cognition rather than memory function (mediated by medial temporal) would be the targeted area for potential improvement. This single center, double blind, placebo controlled study compares a group of PD patients treated with galantamine to a group of PD patients who are not treated with this medication on a series of cognitive tasks that examine attention and executive control.

Official Title
-----------------
Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Drug: galantamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Idiopathic Parkinson's Disease Exclusion Criteria: dementia, depression, cardiac disease, gastrointestinal disease

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: galantamine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement on cognitive measures |  | 16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| No worsening of PD symptoms |  | 16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cognition
Prognosis of Low-grade Endometrial Stromal Sarcoma

Study Overview
=================
Brief Summary
-----------------
This study is to investigate the survival outcomes and fertility outcomes in patients with uterine low-grade endometrial stromal sarcoma (LGESS) treated in Peking Union Medical College Hospital. All primary and recurrent LGESS patients will be enrolled. The study will collect retrospectively data consisting of epidemiological characteristics, surgical, medical treatment and adjuvant therapy. Details about recurrence, mortality, pregnancy and obstetrical outcomes are also followed as primary endpoints. Fertility-sparing procedures, including uterine-sparing and ovary-sparing surgeries will be recorded specifically.

Official Title
-----------------
Surgical and Reproductive Results of Fertility-sparing Treatment for Low-grade Endometrial Stromal Sarcoma: A Retrospective Cohort Study

Conditions
-----------------
Low Grade Endometrial Stromal Sarcoma of Uterus (Diagnosis), Fertility-sparing Surgery, Survival Outcomes, Fertility Outcomes, Recurrence, Hormone Therapy, Adjuvant Therapy

Intervention / Treatment
-----------------
* Procedure: Surgical treatment with and without fertility-sparing procedures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years or older Confirmed of LGESS Acceptance of surgical treatment for LGESS With detailed follow-up outcomes Exclusion Criteria: - Not meeting all of the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Surgical treatment with and without fertility-sparing procedures|Patients accepted surgeries for LGESS and relevant adjuvant therapy if indicated.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression-free survival after surgery | One year | 
| Overall survival | Overall survival after surgery | One year | 
| Pregnancy rate | Pregnancy rate after surgery in patients with fertility-sparing patients | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Miscarriage rate | Miscarriage rate after surgery in patients with fertility-sparing patients | One year | 
| Full-term pregnancy rate | Full-term pregnancy rate after surgery in patients with fertility-sparing patients | One year |
Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determinate if mediyoga has effects in quality of life, heart rate variability, blood pressure , heart rate in patients with paroxysmal atrial fibrillation (PAF).

Detailed Description
-----------------
This is randomized prospective pilot study. Eighty patients from Danderyd hospital, Stockholm, Sweden were randomized to either mediyoga group or control group. The mediyoga group were completing yoga for one hour, once a week for 12 weeks together with usual treatment. The controlgroup had only usual treatment.The usual treatment consists of pharmaceutical, cardio version and ablation. Quality of life ( SF-36, EQ-5d), blood pressure, heart rate and 24-hours ekokardiografi were measured at baseline and after twelve weeks.A follow up after six months was accomplished with SF-36 and EQ-5d, bloodpressure and heart rate.

Official Title
-----------------
Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation

Conditions
-----------------
Paroxysmal Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of PAF Exclusion Criteria: The exclusions criteria were multiple concurrent medical conditions and/or cognitive dysfunction (in the diagnosis of e.g. mental illness), considered not to be able to carry out yoga owing to ability to move and those who have difficulties to understand the Swedish language.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life |  | Change from baseline in SF-36 after 12 weeks.Change from baseline in SF-36 after six months. | 
| Quality of life |  | Change from baseline in SF-36 after 12 weeks.Change from baseline in EQ-5D after six month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure |  | Change from baseline in blood pressure after 12 weeks. Change from baseline in blood pressure after six months | 
| heart rate |  | Change from baseline in heart rate after 12 weeks.Change from baseline in heart rate after six months. | 
| Heart variability |  | Change from baseline in heart variability after 12 weeks.Change from baseline in heart variability after six months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
paroxysmal atrial fibrillation, yoga, quality of life, blood pressure, heart rate, heart rate variability
Measurement of Revascularization Effect Using NIRS in BTK Arteries

Study Overview
=================
Brief Summary
-----------------
Patient with occluded below the knee arteries and chronic limb ischemia Rutherford class V-VI are enrolled. During endovascular recanalisation procedure changes in tissue oxygen amount is recorded using near infrared spectroscopy (NIRS). Primary hypothesis - NIRS can be used to determine sufficient amount of blood reaching the ulcered ishemic area. Secondary hypothesis - NIRS can be useful in detecting early recoil after BTK recanalisation.

Official Title
-----------------
Measurement of Revascularization Effect Using Near Infrared Spectroscopy in Below the Knee Arteries

Conditions
-----------------
Percutaneous Transluminal Angioplasty, Wound Heal, Ischemic Feet

Intervention / Treatment
-----------------
* Diagnostic Test: Intraoperative NIRS monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critical limb ischemia Rutherford V-VI At least one artery below the knee is planned to revascularize Exclusion Criteria: Blood oxygen saturation below 85% because of any comorbidities Life expectancy less than 12 months Unavoidable amputation above ankle Skin diseases preventing the use of NIRS

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Intraoperative NIRS monitoring|Near infrared spectroscopy non invasively used to register changes in tissue oxygen amount during endovascular revascularization|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase in oxygen amount sufficient for wound healing |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of early recoil after BTK revascularization |  | 1 hour |
Expression of NIS Protein and mRNA in Thyroid Tumors

Study Overview
=================
Brief Summary
-----------------
The uptake of iodide by thyroid cells requires the expression of sodium iodide symporter (NIS). Thyroid benign and malignant tumors have low iodide uptake activity. Previous studies of NIS expression with RT-PCR and immunohistochemistry showed divergent data. NIS protein was overexpressed in thyroid cancer. The aim of this study was to investigate the NIS transcript levels and its presence and localization in 30 samples of thyroid tumors (14 benign and 16 malignant) and in their surrounding non-tumoral tissues (NT), by real time RT-PCR and immunohistochemistry, respectively. Our results revealed lower gene expression in 78.6% of the benign tumors and 100% of the carcinomas when compared with the NT samples, using GHPDH as a housekeeping gene. Immunohistochemical staining revealed presence of NIS protein in 100% of the non-tumoral samples, 100% of the benign tumors and 93.75% of the malignant tumors. NIS protein was identified at basolateral membrane in 23.3% of non-tumoral samples, 14.3% of benign and 12.5% of malignant tumors. Stronger cytoplasmatic immunostaining of NIS protein was detected in 64.3% of benign tumors and in 87.5% of malignant tumors when compared to NT. Association between low gene expression and strong cytoplasmatic immunostaining was found in 50% of benign tumors and 87.5% of malignant tumors. We concluded that the reduced NIS gene expression in thyroid tumors associated with strong intracytoplasmatic staining may be due to its incapacity to migrate to cellular membrane.

Detailed Description
-----------------
The aim of this study was to quantify NIS transcript levels by real time PCR and to determine the presence and cellular localization of NIS protein by immunohistochemistry, in benign and malignant thyroid tumor cells and to compare with their paired surrounding non-tumoral cell. NIS expression was also compared to that of the TSHR

Official Title
-----------------
Significant Intracellular NIS Protein Associated With Low Levels of NIS Messenger RNA in Malignant Thyroid Tumors

Conditions
-----------------
Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PAtients with thyroid tumors undergoing surgery for total or partial thyroidectomy Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NIS, thyroid adenoma, thyroid cancer, Iodine uptake, expression
Vaginal Elasticity Assessment Before and After Vaginal Carbon Dioxide Laser Treatment.

Study Overview
=================
Brief Summary
-----------------
Female patients with either stress urinary incontinence (SUI) or vaginal wall weakness and prolapse will be evaluated for vaginal elasticity using vaginal tactile imaging both before and after Carbon Dioxide laser treatment.

Detailed Description
-----------------
Patients will be recruited and sign a consent form. The patients included are patients with SUI or vaginal wall weakness and prolapse. Each participant undergoes 3 laser treatments 4 weeks apart. Assessment of vaginal elasticity via vaginal tactile imaging will be performed at 3 different points: Before the first treatment session (baseline). Before and after each treatment session. 3 months post final treatment. Every patient will serve as her own control. Demographic, gynecologic and obstetric history will be obtained from patients' electronic files.

Official Title
-----------------
Vaginal Elasticity Assessment Before and After Vaginal Carbon Dioxide Laser Treatment.as Measured by Vaginal Tactile Imaging.

Conditions
-----------------
Laser Burn

Intervention / Treatment
-----------------
* Diagnostic Test: Vaginal Tactile Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any woman undergoing vaginal Carbon Dioxide laser treatment. Exclusion Criteria: Women that are not in the age range.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Laser treatment<br>Female patients with either SUI of vaginal wall weakness and prolapse refered for an attempt at laser treatment. | Diagnostic Test: Vaginal Tactile Imaging<br>* Vaginal Tactile Imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaginal elasticity assessment | Vaginal elasticity as measured by the vaginal tactile imager | up to 3 months from enrollment |
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD

Study Overview
=================
Brief Summary
-----------------
This noninterventional study will assess genomic changes in the metabotropic glutamate receptor (mGluR) network in children and adolescents with ADHD.

Detailed Description
-----------------
Male and female subjects 6 to 17 years of age with a primary psychiatric diagnosis of ADHD will be enrolled in this study. The subject and his or her parent/guardian must agree to genotyping to determine whether the subject has disruptive mutations within any of the approximately 274 mGluR-network genes, and complete an interview that will include information about the subject's ADHD history, treatment, and co-morbidities.

Official Title
-----------------
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Conditions
-----------------
Attention Deficit Disorder With Hyperactivity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The subject is male or female ≥6 and ≤17 years of age. The subject has ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition. The subject, his or her legally responsible representative, and investigator agree to complete ADHD history, treatment, and comorbidity electronic case report form (eCRF). Exclusion Criteria: The subject or parent/legal guardian is in the opinion of the investigator mentally or legally incapacitated and unable to provide informed consent/assent for participation in the study.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of mGluR network mutations |  | At study enrollment |
Donor Gender Effect on Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant

Study Overview
=================
Brief Summary
-----------------
Liver transplantation (LT) represents the gold-standard therapy for the treatment in case of dreadful liver pathologies . It is thus a main concern to optimize the results in terms of post-LT survivals. The effect of gender match on post-transplant outcome is still debatable. Hormonal , and size difference between female and male may be proposed to affect the post transplant outcome . The aim of this study is to evaluate the effect of donor-recipient gender mismatch on survival rates

Official Title
-----------------
Donor Gender Effect on Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant: A Single Centre Retrospective Study

Conditions
-----------------
Donor to Recipient Gender Mismatch in LDLT

Intervention / Treatment
-----------------
* Other: non interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Egyptian Patients >18 years. Exclusion Criteria: Patient refusal. Patients who underwent re-transplantation before discharge from the ICU after the first liver transplant. Intraoperative cardiac arrest or immediately postoperative cardiac arrest within the first 6 hours postoperative. Massive blood loss. Pre-existing renal failure requiring hemodialysis or continuous hemofiltration. Pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Matched group<br>Same sex of both donor and recipient | Other: non interventional<br>* non interventional study<br>|
| Mismatched group<br>Sex mismatch between donor and recipient, subgroups might be added | Other: non interventional<br>* non interventional study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 2 years survival post liver transplant. | The primary outcome will be survival at 2 years post liver transplant | 3 months |